Market analytics and operational performance indicators
Rocket Lab SEC Filings
Browse Rocket Lab filings, review key metrics, and open source documents from one place.
SEC Command Deck
Use this feed to separate quarterly and annual operating disclosures from one-off event filings and insider ownership changes before opening full analysis or source documents.
What matters now
Latest Filings
Read the brief first, then open the full filing only when you need document-level detail.
Merline Saintil, Director at Rocket Lab USA, sold 5,000 common shares on 12/17/2025 in multiple transactions at weighted-average prices from $53.82 to $56.48. Post-transaction direct holdings: 393,529 shares. Neutral signal due to pre-scheduled Rule 10b5-1 trading plan.
Rocket Lab director Merline A. Saintil filed Form 144 on 12/17/2025 to sell 5,000 common shares (market value $277,450) acquired via RSUs in 2023. This follows recent sales of 25,000 shares on 12/4 and 12/12/2025 totaling ~$1.455M. The sale relies on a Rule 10b5-1 plan adopted 9/17/2025, indicating pre-planned trading.
Merline Saintil, Director at Rocket Lab USA, sold 15,000 shares of common stock on 12/12/2025 at $65 per share, totaling ~$975K. This reduced her direct holdings to 398,529 shares. The discretionary sale (no 10b5-1 indicated) is a moderate bearish signal.
Rocket Lab CEO Peter Beck's family trust executed multiple sales totaling 2.5 million shares on Dec 15-16, 2025, pursuant to a Rule 10b5-1 trading plan adopted in June 2025. The transactions liquidated the trust's holdings to zero, with shares sold at weighted average prices ranging from $53.21 to $64.31. This is a neutral signal as it is a pre-scheduled, non-discretionary sale.
Form 144 discloses Rocket Lab CEO Peter Beck's proposed sale of 2,500,000 Class A shares valued at $138.5 million on December 15, 2025. Shares, acquired via 2021 business combination conversion, will be sold by Equatorial Trust under a Rule 10b5-1 plan adopted June 13, 2025. Recent September 2025 sales by the Trust totaled ~2.5M shares for $127.5M; relevant for tracking insider liquidity amid RKLB's growth.
Form 144 discloses Rocket Lab director Merline A. Saintil's proposed sale of 15,000 common shares, valued at $975,000, on 12/12/2025. Shares stem from 2023 RSU vesting as compensation. This follows her sale of 10,000 shares on 12/04/2025 for $480,000, providing insight into insider liquidity events relevant to investor sentiment.
Director Merline Saintil sold 10,000 shares of Rocket Lab (RKLB) common stock on 12/04/2025 at $48 each, totaling $480K. She now holds 413,529 shares directly. This discretionary sale (no 10b5-1 plan) is moderately bearish.
Rocket Lab director Merline A. Saintil filed Form 144 to sell 10,000 common shares acquired via 2023 RSU vesting, valued at $480,000. No sales reported in past 3 months; sale planned for 12/04/2025 via Morgan Stanley. Routine insider disclosure enhances transparency for investors.
Rocket Lab officer Arjun Kampani filed Form 144 on 11/26/2025 to sell 10,554 common shares valued at $449,600, acquired from RSU vesting on 11/22/2025. The proposed sale follows a Rule 10b5-1 trading plan adopted 12/12/2024. Recent sales include 28,615 shares on 11/24/2025 ($1.16M), disclosing routine insider activity relevant for monitoring executive confidence.
Frank Klein, a Rocket Lab officer, filed Form 144 on November 26, 2025, notifying of intent to sell 4,736 common shares acquired via RSUs vesting on November 22, 2025, with aggregate value $201,753.60. The sale follows a Rule 10b5-1 plan adopted December 13, 2024, and prior sales of ~91,603 shares in past 3 months totaling ~$4.33M. Relevant to investors tracking insider activity amid routine compensation vesting.
Director Saintil sold 5,000 shares ($272K) via 10b5-1 plan.
Key Telemetry
- • Sold 5,000 shares (~1.3% of post-sale direct holdings of 393,529)
- • Executed under 10b5-1 plan adopted 9/17/2025 (standard scheduled sale)
Rocket Lab director Merline Saintil files Form 144 to sell 5,000 shares under 10b5-1 plan.
Key Telemetry
- • Director Merline Saintil to sell 5,000 common shares (~$277k value) on 12/17/2025.
- • Recent sales: 10k shares (12/4, $480k), 15k shares (12/12, $975k); total 25k shares past 3 months.
Director Saintil sold 15,000 shares ($975K) at $65.
Key Telemetry
- • Sold 15,000 shares (~3.8% of post-sale direct holdings of 398,529 shares)
- • Discretionary open-market sale; no 10b5-1 plan indicated
CEO Beck's trust sold 2,500,000 shares ($141M) via 10b5-1 plan.
Key Telemetry
- • Sold 2,500,000 shares (100% of trust holdings, ~73% of Beck's total prior ~3.4M shares) for ~$141M.
- • Executed under 10b5-1 plan adopted June 13, 2025 (6 months prior).
CEO Peter Beck to sell 2.5M RKLB shares worth $138.5M under 10b5-1 plan.
Key Telemetry
- • Peter Beck proposes sale of 2,500,000 Class A shares ($138.5M aggregate value) on 12/15/2025.
- • Sales by Equatorial Trust under Rule 10b5-1 plan adopted 6/13/2025.
Director Merline Saintil to sell 15,000 RKLB shares worth $975,000.
Key Telemetry
- • Director Merline A. Saintil proposes sale of 15,000 common shares ($975,000 value) on 12/12/2025.
- • Shares acquired 08/22/2023 via RSU vesting as compensation.
Director Saintil sold 10,000 shares ($480K) at $48.
Key Telemetry
- • Sold 10,000 shares (~2.4% of post-sale holdings of 413,529 shares)
- • Discretionary sale (no 10b5-1 plan indicated)
Director Merline Saintil to sell 10,000 RKLB shares worth $480K.
Key Telemetry
- • Merline Saintil (Director) to sell 10,000 common shares on ~12/04/2025.
- • Shares from 08/22/2023 RSU vesting; value $480,000 ($48/share).
Officer Arjun Kampani files Form 144 to sell 10,554 RKLB shares under 10b5-1 plan.
Key Telemetry
- • Arjun Kampani (officer) to sell 10,554 common shares (~$449,600) on ~11/26/2025 via Morgan Stanley.
- • Shares acquired 11/22/2025 from RSU vesting; under 10b5-1 plan adopted 12/12/2024.
Rocket Lab officer Frank Klein files Form 144 to sell 4,736 shares under 10b5-1 plan.
Key Telemetry
- • Officer Frank Klein to sell 4,736 common shares (value $201,753.60) on 11/26/2025, from RSUs vested 11/22/2025.
- • Sale under 10b5-1 plan adopted 12/13/2024.